Low-Dose Interlukin-2 as Supportive Therapy for Systemic Lupus Erythematosus with Nontuberculous Mycobacterial Pneumonia: A Case Report

Ho W1,2#, Jiang Y3#, Zhang X1,2 and Ye H1,2*

1Department of Rheumatology & Immunology and Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People's Hospital, China
2Center of Clinical Immunology, Peking University, China
3Department of Rheumatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, China
#These authors contributed equally to this work

^*Correspondance to: Hua Ye 

 PDF  Full Text Case Report | Open Access

Abstract:

A young woman with Systemic Lupus Erythematosus (SLE) was initially treated with prednisone, Mycophenolate Mofetil (MMF), Leflunomide (LEF) and Hydroxychloroquine (HCQ). After maintenance treatment for about 3 years, the patient developed recurrent pneumonia of Nontuberculous Mycobacterial (NTM) infection. After reducing immunosuppressants, she developed a flare of SLE but infection was still persisted. Therefore, Low-dose Interlukin-2 (Ld IL-2) was added to the treatment, and got promising effects finally. SLE patient received long-term of glucocorticoids and immunosuppressants therapy are prone to get infected, how to balance infection and immunosuppressive therapy is a difficult problem. Ld IL-2 can promote Treg cells for tolerance, and invigorate NK and CD8+ T cells against infection. Ld IL-2 therapy might be a new option for SLE patients, especially when complicated with infection.

Keywords:

Immunosuppressants; Low-dose interlukin-2; Nontuberculous mycobacterial pneumonia; Systemic lupus erythematosus

Cite the Article:

Ho W, Jiang Y, Zhang X, Ye H. Low- Dose Interlukin-2 as Supportive Therapy for Systemic Lupus Erythematosus with Nontuberculous Mycobacterial Pneumonia: A Case Report. Ann Clin Case Rep. 2024; 9: 2652..